Systemic IFN-Alpha Treatment of Multiple Bladder Papilloma Grade I or II Patients: Pilot Study

Publisher Website
Google Scholar
Abstract
Bladder papillomatosis offers a good target to evaluate IFN-α systemic treatment. We carried out a pilot study on eight multiple bladder papilloma patients under the same treatment scheme (1 × 106 IU/amp. every 48 h over six months), and they were followed-up for over two years after treatment. Recurrent patients underwent a similar second treatment. IFN-α therapy showed the following variations of effects: total disappearance, size decrease or persistence of papillomas, neither size increase nor appearance of new ones, remarkable valuable recurrence frequency rate decrease in all cases, and recurrences with smaller papillomas. This IFN-α treatment scheme would be fit to carry out broader controled studies to show frequencies of the different kinds of responses. The inclusion of a minimum (dose-frequency-period) IFN-α treatment period after the first six months' therapy is proposed in order to achieve total disappearance of recurrences.